Diffuse large B-cell lymphoma
What is diffuse large B-cell lymphoma (DLBCL)?
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that develops from the B-cells in the lymphatic system. Under the microscope, large malignant lymphocytes are seen diffusely throughout the specimen.
DLBCL is the most common subtype of non-Hodgkin lymphoma accounting for 30%-40% of all cases. There are several types of DLBCL, with most people being diagnosed with the subtype known as DLBCL ‘not otherwise specified’. Rarer types include:
- Primary mediastinal large B-cell lymphoma: accounts for 2-4% of all non-Hodgkin lymphomas. Can occur at any time from early adulthood, but is most common between 25-40 years of age. It is twice as common in women as in men. Develops in the mediastinum (in the chest) and can cause problems due to the pressure of the mass on the lungs or gut, or on the superior vena cava (the second largest vein in the body which returns blood from the upper half of the body to the heart).Symptoms include breathlessness, persistent cough, difficulty swallowing (dysphagia), swelling of the neck and face, dizziness and headaches. Treatment involves the use of a targeted therapy plus standard chemotherapy, often followed by radiotherapy or high-dose chemotherapy regimens. Stem cell transplants may be offered if this type of lymphoma relapses.
- T-cell/histiocyte-rich large B-cell lymphoma: more common in men aged over 50 years but can affect people of any age. Fewer than 10% of people with DLBCL will have this type. This type of DLBCL has all three types of cells present- T-cells, histiocytes and large B-cells, when viewing a biopsy specimen under the microscope. Symptoms include swollen lymph nodes, fever and swelling of the liver or spleen. People with this type of DLBCL will feel generally unwell and have abdominal swelling and discomfort. Treatment is similar to that of the more common types of DLBCL (such as a targeted therapy plus standard chemotherapy). If it relapses, the other high-dose chemotherapy regimens mentioned below may be used. Stem cell transplantation may also be an option for some people.
- Intravascular large B-cell lymphoma: extremely rare form of lymphoma. Occurs in adults with the average age at diagnosis being 65 years. Malignant lymphocytes are found within small blood vessels meaning it could affect just about any part of the body, although it is rare to find it in the bone marrow or lymph nodes.Symptoms vary depending on which small blood vessels are affected, but 75% of people with this form of DLBCL experience stroke-like symptoms; for example, weakness, numbness or paralysis in the face, arm or legs on either or both sides of the body, difficulty speaking or understanding, dizziness, loss of balance or unexplained falls, changes in vision, severe headaches, and difficulty swallowing. These symptoms are a result of the impact of the lymphoma on the nervous system. Some people may also develop patches of inflamed skin across their body or experience fevers, night sweats and unexplained weight loss. Intravascular large B-cell lymphoma is often treated with a targeted therapy plus standard chemotherapy and/or more aggressive therapies if suitable for that particular person.
How does diffuse large B-cell lymphoma affect the body?
Often the first symptom of DLBCL is a painless swelling in the neck, armpit or groin that is caused by enlarged lymph nodes. These lumps can grow quite quickly, often over a period of a few weeks. Sometimes, other parts of the body are also affected. This is known as ‘extranodal’ disease because it is happening outside of the lymph nodes, and includes the stomach or bowel being affected, which may cause abdominal discomfort or pain, diarrhoea or bleeding. DLBCL can also be found in many other areas including the salivary glands, nasal sinuses, liver, lungs, testes, skin, brain or eye with symptoms being directly related to the amount of pressure the lymphoma is putting on the particular body part that is affected. Other general symptoms experienced by people with DLBCL include fevers, night sweats and unexplained weight loss.
Who does diffuse large B-cell lymphoma commonly affect?
DLBCL can occur at any age, but is most common in people aged over 50 years. The average age of diagnosis is 60-65 years; however, DLBCL can also affect children. It is slightly more common in men than in women. It is not due to infection and cannot be passed from one person to another. DLBCL may develop independently or in some instances may develop in people who have been diagnosed with a low-grade lymphoma in the past (i.e. low-grade lymphoma can transform to DLBCL).
What causes diffuse large B-cell lymphoma?
Whilst the exact causes of DLBCL are unknown, people who have a compromised immune system may be more susceptible to developing DLBCL. This may include people who have previously been treated for other forms of cancer including a low-grade lymphoma, or people who have an autoimmune disorder.
How is diffuse large B-cell lymphoma treated?
DLBCL is high-grade (fast-growing) and needs to be treated quickly. The current treatment is a targeted therapy plus standard chemotherapy. This treatment usually continues for approximately 4 months. Other therapies include radiation, stem cell transplants and other chemotherapy. If the DLBCL relapses after initial treatment, several chemotherapy regimens can be used. If the DLBCL has infiltrated the cerebrospinal fluid, additional chemotherapy can be given directly into the spinal cord. DLBCL is very responsive to treatment with a large percentage of people being cured.
Last updated on June 20th, 2020
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.